

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/062,587	2,587 01/31/2002		Harvey D. Preisler	047940-0135	1948
23524	7590	01/08/2004		EXAM	INER
FOLEY &			CANELLA, KAREN A		
150 EAST GILMAN STREET P.O. BOX 1497			ART UNIT	PAPER NUMBER	
MADISON,	MADISON, WI 53701-1497			1642	
				DATE MAILED: 01/08/2004	!

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	10/062,587	PREISLER, HARVEY D.
Office Action Summary	Examiner	Art Unit
	Karen A Canella	1642
The MAILING DATE of this communi	ication appears on the cover sheet w	th the correspondence address
Period for Reply	OD DEDLY 10 OFF TO EVOIDE 414	0.17.1/0. 50.01
A SHORTENED STATUTORY PERIOD FOR THE MAILING DATE OF THIS COMMUNITY. - Extensions of time may be available under the provisions after SIX (6) MONTHS from the mailing date of this community. - If the period for reply specified above is less than thirty (30). - If NO period for reply is specified above, the maximum state. - Failure to reply within the set or extended period for reply: - Any reply received by the Office later than three months at earned patent term adjustment. See 37 CFR 1.704(b). - Status	CATION. of 37 CFR 1.136(a). In no event, however, may a r unication. O) days, a reply within the statutory minimum of thin tutory period will apply and will expire SIX (6) MON will, by statute, cause the application to become AE	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).
1) Responsive to communication(s) file	d on	
	b)⊠ This action is non-final.	
3) Since this application is in condition to closed in accordance with the practic	,— for allowance except for formal matt	
Disposition of Claims		
4) Claim(s) 1-51 is/are pending in the a	pplication.	
4a) Of the above claim(s) is/ar	• •	
5) Claim(s) is/are allowed.		
6) Claim(s) is/are rejected.		·
7) Claim(s) is/are objected to.	*	
8) Claim(s) <u>1-51</u> are subject to restriction	on and/or election requirement.	
Application Papers		
9) The specification is objected to by the		
10) The drawing(s) filed on is/are:		·
Applicant may not request that any object		• •
Replacement drawing sheet(s) including	-	• • •
11) The oath or declaration is objected to	by the Examiner. Note the attached	Office Action of form P10-752.
Priority under 35 U.S.C. §§ 119 and 120	for foreign priority and as 25 H O O	2.440(=) (4) == (6)
12) Acknowledgment is made of a claim a) All b) Some * c) None of:	ior foreign priority under 35 U.S.C. §	119(a)-(d) or (t).
1. ☐ Certified copies of the priority of		
2. Certified copies of the priority of 3. Copies of the certified copies of		
application from the Internation		received in this Ivational Stage
* See the attached detailed Office action		
13) Acknowledgment is made of a claim fo since a specific reference was included		
37 CFR 1.78. a) ☐ The translation of the foreign lang	guage provisional application has be	en received
14) Acknowledgment is made of a claim fo	- ·	
reference was included in the first sente		
Attachment(s)		
1) Notice of References Cited (PTO-892)		ummary (PTO-413) Paper No(s)
Notice of Draftsperson's Patent Drawing Review (PT 3) Information Disclosure Statement(s) (PTO-1449) Pa		formal Patent Application (PTO-152) .

U.S. Patent and Trademark Office PTOL-326 (Rev 11-03)

Office Action Summan

Application/Control Number: 10/062,587

Art Unit: 1642

4

DETAILED ACTION

1. Claims 1-51 are pending.

Election/Restrictions

- 2. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-21, 32, 33 and 39-45, drawn to isolated polypeptides comprising SEQ ID NO:1-31 and variants thereof having one or more conservative amino acid substitutions, isolated polypeptides which preferentially bind to the surface of a blood cell, kits containing said polypeptides and variants, classified in class 530, subclass 300.
 - II. Claims 22-31, 34-38 and 46-51, drawn to a method of binding the peptides of Group I to a cell or a cellular component and a method of inducing the differentiation of acute myelogenous leukemia cells comprising contacting said cell with isolated polypeptides, classified in class 514, subclass 2.
- 3. The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the isolated peptides of Group I can be used in a method of raising an antibody.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and recognized divergent subject matter and because the searches required for the groups are not co-extensive, restriction for examination purposes as indicated is proper.

4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Application/Control Number: 10/062,587

Art Unit: 1642

- 5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 6. This application contains claims directed to the following patentably distinct species of the claimed invention: the sequences of SEQ ID NO:1-31

Applicant is required under 35 U.S.C. 121 to elect a single disclosed sequence species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1, 2, 18-51 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Canella whose telephone number is (703) 308-8362. The examiner can normally be reached on Monday through Friday from 8:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by

Page 4

telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached on (703) 308-3995. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Moren A. Ganella. Karen A. Canella, Ph.D.

Patent Examiner, Group 1642

12/21/03